ArticleCurrent medicinal chemistry2026
Curcumin Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells from Anterior Cruciate Ligament Reconstruction via ERK1/2 Pathway.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurcumin and bone marrow-derived mesenchymal stem cells (BMSCs) with osteogenic differentiation potential can promote tendon-bone healing. This study revealed the specific mechanisms by which curcumin promotes osteogenic differentiation of BMSCs. MATERIALS AND
methodsBMSCs were isolated from mice undergoing anterior cruciate ligament reconstruction (ACLR) or from control mice and subsequently characterized using flow cytometry. CCK-8 and flow cytometry were used to assess the survival and apoptosis of ACLR-modeled BMSCs with or without curcumin treatment, and the osteogenic potential in vitro was evaluated via alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining. The levels of relevant downstream mediators were measured by qRTPCR and immunoblotting. A rescue assay was performed to validate the interplay between curcumin and the extracellular signal-regulated protein kinase (ERK) pathway using the ERK inhibitor U0126.
resultsThe isolated cells were characterized as positive for CD44, CD90, and CD105, and negative for CD45 and CD34, confirming their phenotype as BMSCs. Curcumin intervention promoted the survival and osteogenic potential of CD44+CD90+CD105+ ACLR/ BMSC and inhibited apoptosis in vitro; however, these promoting effects were negated following treatment with ERK inhibitor U0126. Moreover, U0126 reversed the promoting effects of Curcumin on the phosphorylation of ERK1/2 and BAD in vitro. DISCUSSION: This study investigated the potential effects of curcumin on the osteogenic differentiation of CD44+CD90+CD105+ ACLR/BMSCs in vitro, providing novel evidence for the therapeutic potential of curcumin in ACLR.
conclusionCurcumin can enhance the osteogenic differentiation potential of CD44+CD90+CD105+ ACLR/BMSCs in vitro via the ERK pathway, thereby promoting tendon-bone healing following ACLR. However, these findings require further experimental validation.
Indexed as
Identifiers
42768848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.